|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical records were reviewed and tissue specimens were genetically tested for the presence of the most commonly encountered mutational markers in differentiated thyroid cancer: BRAF, N-RAS, and H-RAS.
|
31586312 |
2019 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer.
|
30717896 |
2019 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma.
|
31093278 |
2019 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation profiles of advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer have revealed the pathogenic roles of the established oncogenic mutations of BRAF and PI3KCA, but the involvement of other genes is presently unknown.
|
30323976 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF = B-Raf proto-oncogene, serine/threonine kinase; CI = confidence interval; CT = computed tomography; DTC = differentiated thyroid cancer; FDG = fluorodeoxyglucose; PET = positron emission tomography; PTC = papillary thyroid cancer; SUV = standardized uptake value.
|
29144823 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because BRAF and RAS mutations are the most common molecular perturbations associated with well-differentiated thyroid cancer, these findings may assist with improved preoperative risk assessment by suggesting the likely molecular profile of a thyroid cancer, even when postsurgical molecular analysis is unavailable.
|
27689252 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, BRAF mutations were identified in 48.5 % (99/204) of adult DTCs.
|
27387551 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were detected in 25 DTCs (4.5%): 2.8% in neither BRAF-mutated nor RAS-mutated tumors, 4.8% in BRAF-mutated tumors, and 11.3% in RAS-mutated tumors.
|
26969876 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Frequent coexistent TERT promoter and BRAF or RAS mutations in metastatic DTC also suggests its important role in the progression of DTC.
|
26971368 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the differences in glucose metabolism of the BRAF(V600E) mutation versus BRAF wild-type (BRAF-WT) in patients with metastatic differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).
|
25814520 |
2015 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Well-differentiated thyroid cancer with a minor poorly differentiated component: clonal heterogeneity through the prognostic role of CXCR4 and BRAF analysis.
|
24992171 |
2015 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dabrafenib was well tolerated and resulted in durable responses in BRAF-mutant differentiated thyroid carcinoma patients.
|
25285888 |
2015 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither the presence of V600E BRAF mutations nor that of a well-differentiated thyroid carcinoma changed the outcome or disease-free survival.
|
24777145 |
2014 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyroid nodules of differentiated thyroid cancer, representing a 100% diagnostic specificity and 7.0% sensitivity, with the latter rising to 38.0% (49/129) when combined with BRAF V600E testing.
|
25121551 |
2014 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several diagnostic and prognostic molecular markers such as BRAF and RAS point mutations; RET/PTC and PAX8/PPARγ gene rearrangements; MAPK, PI3K, p53, Wnt-beta catenin, HIF1α and NF-kappaB signaling pathways; microRNA profiles and aberrant methylation have been demonstrated in more than 70% of DTC.
|
24405857 |
2014 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation was present in 65% of 94 DTC and p.Q61R NRAS in one.
|
24468978 |
2014 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic alterations in the mitogen-activated protein kinase pathway, including mutations of BRAF, RAS, and RET genes, have been implicated in the development of differentiated thyroid carcinoma arising in the thyroid gland.
|
19898969 |
2010 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
|
19356676 |
2009 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DTC was present in half of the cases.BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had identical mutations in both the ATC and DTC components.
|
17989125 |
2008 |